Abstract
A selection of previously identified protective Mycobacterium tuberculosis DNA vaccines were re-formulated as proteins and administered with a Th1-inducing adjuvant to help stimulate the relevant immune responses necessary for protection. All three candidate-vaccines conferred high levels of antigen-specific cellular and humoral responses, as indicated by lymphocyte proliferation and serum IgG levels. Protective efficacy was also assessed in comparison with the current vaccine, BCG (the 'gold-standard' against which new vaccines are tested), and a saline (negative) control. One candidate (Rv1806-1807) induced protection in the guinea pig aerosol infection model 30 days post-challenge on the basis of reducing the bacterial burden of M. tuberculosis in the lungs.
Publication types
-
Comparative Study
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic
-
Animals
-
Antibodies, Bacterial / blood
-
Antigens, Bacterial / immunology
-
Cell Proliferation
-
Cells, Cultured
-
Disease Models, Animal
-
Epitopes
-
Escherichia coli / genetics
-
Female
-
Genes, Bacterial
-
Genetic Vectors
-
Guinea Pigs
-
Immunity, Cellular
-
Immunoglobulin G / blood
-
Lung / microbiology
-
Mycobacterium tuberculosis / genetics
-
Mycobacterium tuberculosis / immunology
-
Mycobacterium tuberculosis / isolation & purification
-
Th1 Cells / immunology
-
Tuberculosis Vaccines / administration & dosage
-
Tuberculosis Vaccines / immunology*
-
Tuberculosis, Pulmonary / immunology
-
Tuberculosis, Pulmonary / prevention & control*
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / immunology*
-
Vaccines, Subunit / administration & dosage
-
Vaccines, Subunit / immunology
Substances
-
Adjuvants, Immunologic
-
Antibodies, Bacterial
-
Antigens, Bacterial
-
Epitopes
-
Immunoglobulin G
-
Tuberculosis Vaccines
-
Vaccines, DNA
-
Vaccines, Subunit